

**PATENTS**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant: Kawai, *et al.*

Group Art No.: 1653

Serial No.: (not yet assigned)

Examiner: (not yet assigned)

Filed: July 10, 2003

For: Antiangiogenic Drug to Treat Cancer,  
Arthritis, and Retinopathy

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the:

Mail Stop Patent Application  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450 on:

Case No.: 6357.US.D1

Date of Deposit: July 10, 2003

Tanya Parent 7/10/03  
Tanya Parent Date

Mail Stop Patent Application  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT**

Dear Sir:

Pursuant to 37 C.F.R. §§ 1.56 and 1.97, Applicants bring to the attention of the Examiner the documents listed on the attached PTO 1449. Applicants respectfully petition and request that the Examiner consider the listed documents and evidence such consideration by making appropriate notations on the attached form.

Applicants submit herewith the Form PTO-1449 listing the references cited in this Information Disclosure Statement. The listed references are available for the Examiner to review in the file of the U.S. Serial No. 09/466,719. If the Examiner needs further copies of any cited references, the Examiner is respectfully requested to contact the undersigned attorney.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

The Commissioner is authorized to charge our Deposit Account any additional fees (or credit any over payments) that may be required under 37 C.F.R. §§ 1.16 and 1.17 in association with this communication for which full payment has not been tendered.



ABBOTT LABORATORIES  
Telephone: (847) 935-7956  
Facsimile: (847) 938-2623

Respectfully submitted,  
Kawai, *et al.*

Johanna M. Corbin  
Johanna M. Corbin  
Registration No. 51,582  
Attorney for Applicants

## Form PTO - 1449 (Modified)

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Modified) PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 6357.US.D1	SERIAL NO. (not yet assigned)
INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (Use several sheets if necessary)	APPLICANT M. Kawai, et al	
	FILING DATE July 10, 2003	GROUP (not yet assigned)
(37 CFR 1.98 (b))		

## U.S. PATENT DOCUMENTS

EXAMINE R INITIAL	PATENT NUMBER								ISSUE DATE	PATENTEE	CLASS	SUB CLASS	FILING DATE
	4	1	4	7	8	0	2		04/03/79	Cook, et al.			
	4	2	5	1	5	3	1		02/17/81	Doria, et al.			
	4	5	4	0	6	8	9		09/10/85	Muto			
	5	4	4	6	0	6	2		08/29/95	Dellaria			
	5	4	5	3	5	3	3		09/26/95	Luo			
	5	7	0	3	1	9	9		12/30/97	Henze			
	5	7	4	1	9	2	6		04/21/98	Bierer			
	5	8	6	9	6	6	5		02/09/99	Padia			

## FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

	DOCUMENT NUMBER								PUBLIC- ATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUB CLASS	TRANS- LATION	
													YES	NO
	9	4	0	4	1	5	6		03.03.94	PCT				
	9	1	1	9	9	8	0		26.12.91	PCT				
	9	9	6	1	4	0	6		02.12.99	PCT				
	0	1	8	3	2	7	1		04.06.86	EP				
	1	4	9	8	9	9	6		25.01.78	GB				
	2	6	5	4	2	1	5		16.06.77	DE				
	9	7	2	3	5	0	0		03.07.97	PCT				
	9	7	4	1	8	2	4		13.11.97	PCT				

## OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

		Teno, et al., "Development of Selective Inhibitors Against Plasma Kallikrein", <i>Chemical and Pharmaceutical Bulletin</i> , Vol. 39(11), pp. 2930-2936 (1991)
		Goker, et al. "Synthesis and Antiaggregator Activity of Some New Derivatives of 4H-1-Benzopyran-4-one", <i>European Journal of Medicinal Chemistry</i> , Vol. 30, pp. 561-567 (1995)
		Kwon, et al., "Synthesis and Biological Activity of Cinnamaledehydes as Angiogenesis Inhibitors", <i>Bioorganic &amp; Medicinal Chemistry Letters</i> , Vol. 7(19), pp. 2473-2476 (1997)
		Marui, et al., "Chemical Modifications of Fumagillin. II", <i>Chemical and Pharmaceutical Bulletin</i> , Vol. 40(3), pp. 575-579 (1992)

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Form PTO-1449)